August holds 5 big FDA decisions; Spark weighs installment payments for blindness therapy;

> The FDA this month is expected to announce big approval decisions for companies including Bristol-Myers Squibb ($BMY), Alkermes ($ALKS) and Amgen ($AMGN). Report

> In Q2, Endo's ($ENDP) branded pharma revenue increased 27%, while generics posted a 24% top-line rise. Release

> Spark Therapeutics ($ONCE) is weighing installment payments for a gene therapy candidate for blindness that analysts predict will be pricey. Report

> Kwang Dong Pharma will market Orexigen's ($OREX) weight loss drug, Contrave, in South Korea. Report

> Shire ($SHPG) has launched the second annual Excellence in ADHD Patient Group Awards. Release

> People on extended-interval prophylaxis regimens with new, long-acting Biogen ($BIIB) hemophilia therapy Eloctate experienced low bleeding rates in a Phase III study. Release

> GlaxoSmithKline ($GSK) is rolling out a tooth sensitivity awareness campaign for Sensodyne toothpaste in India. Report

And Finally... A U.K. company is preparing to launch the first traditional Chinese medicine approved in the country. Report (sub. req.)

Suggested Articles

The Pharma Lions shortlist for 2019 lives up to its name with just 31 entries making the cut. But it's still good news for the 12 drugmaker finalists.

Pharma companies filed suit Friday to block the new HHS rule that requires drugmakers to put list prices in TV ads.

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.